HACKENSACK, N.J., Aug. 18, 2017 /PRNewswire/ -- Champions
Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development
and sale of advanced technology solutions and products to
personalize the development and use of oncology drugs, today
announced a collaboration with The Addario Lung Cancer Medical
Institute "ALCMI" to develop a novel cohort of PDX models in
patients with ROS1 gene rearrangement. These models will
further expand Champions' TumorGraft bank offerings in non-small
cell lung cancer for translational oncology research for academic
and industry customers. Champions' global infrastructure will
be leveraged to support this multi-year program.
As a patient-driven initiative, ALCMI is leading an
international study, with Champions Oncology contributing its
extensive experience and global infrastructure, to support the
establishment of patient derived xenograft models from patients
with a ROS1 fusion. The unique cohort of PDX models can be used as
a resource for clinical and translational research and support
development of new therapies in patients with ROS1 positive
cancer. The models established will have complete clinical
and molecular annotation.
"Champions Oncology is pleased to partner with ALCMI for this
patient-driven initiative to establish a unique cohort of models in
ROS1 positive cancers," said Angela M. Davies, MD, Chief
Medical Officer, Champions Oncology Inc.
"Champions and ALCMI are combining their respective
infrastructure, expertise and scientific commitment to build PDX
models in this rare subtype of cancer and make those models
available to academic and industry researchers," Dr. Davies said.
"This PDX resource will facilitate development of new therapies and
understanding mechanisms of resistance in ROS1 cancers."
"We are pleased to partner with Champions Oncology, and the
ROS1 patient community, to help advance our shared goal of new and
more effective therapies for affected lung cancer patients
everywhere, via the creation and distribution of these much-needed
research and development models," said Steven Young, ALCMI
President & COO.
About ALCMI
The Addario Lung Cancer Medical Institute (ALCMI, voiced as
"Alchemy"), founded in 2008 as a 501(c)(3) non-profit organization
by lung cancer survivor Bonnie J. Addario, is a patient-centric,
international research consortium driving research otherwise not
possible. Working in tandem with its "partner" foundation the
Bonnie J. Addario Lung Cancer Foundation (ALCF), ALCMI powers
collaborative initiatives in genetic (molecular) testing,
therapeutic discoveries, targeted treatments and early detection.
ALCMI overcomes barriers to collaboration via a world-class team of
investigators from 26 member institutions in the USA, UK, and
Europe, supported by dedicated, centralized research
infrastructures such as standardized biorepositories and data
systems. ALCMI directly facilitates research by combining
scientific expertise found at leading academic institutions with
patient access through its network of community cancer centers –
accelerating novel research advancements to lung cancer patients.
By providing access to critical masses of patient stakeholders,
academic, community and industry researchers, ALCMI and ALCF are
making progress towards their shared goal of transforming lung
cancer into a chronically managed disease by 2023.
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The company's technology
platform is a novel approach to personalizing cancer care based
upon the implantation of primary human tumors in immune-deficient
mice to create TumorGrafts that preserve the biological
characteristics of the original human tumor to determine the
efficacy of a treatment regimen. The company uses this technology
in conjunction with related services to offer solutions for two
customer groups: Personalized Oncology Solutions, in which results
help guide the development of personalized treatment plans, and
Translational Oncology Solutions, in which pharmaceutical and
biotechnology companies seeking personalized approaches to drug
development can lower the cost and increase the speed of developing
new drugs. For more information, please
visit www.championsoncology.com.
View original
content:http://www.prnewswire.com/news-releases/champions-oncology-announces-research-collaboration-with-the-addario-lung-cancer-medical-institute-to-develop-unique-cohort-of-patient-derived-xenograft-pdx-models-300506481.html
SOURCE Champions Oncology, Inc.